Centralia, Illinois Clinical Trials

A listing of Centralia, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with antibodies, such as nivolumab and ipilimumab, may remove the brake on the body's …

psychiatric illness
combination therapy
ct scan
skin cancer
tubal ligation
Centralia Oncology Clinic
 (0.4 away) Contact site
  • 11 views
  • 12 Sep, 2021
  • +288 other locations
Testing The Addition of a New Anti-cancer Drug Venetoclax to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated Older Patients With Chronic Lymphocytic Leukemia

This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment. The addition of venetoclax to the usual treatment might prevent chronic lymphocytic leukemia from returning. This trial also will …

fatigue
rituximab
ibrutinib
venetoclax
lymphoma
Centralia Oncology Clinic
 (0.4 away) Contact site
  • 382 views
  • 15 Sep, 2021
  • +740 other locations
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.. Giving …

Centralia Oncology Clinic
 (0.4 away) Contact site
  • 71 views
  • 16 Sep, 2021
  • +692 other locations
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer STAMP Study

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may …

Centralia Oncology Clinic
 (0.4 away) Contact site
  • 22 views
  • 02 Sep, 2021
  • +434 other locations
Testing the Addition of the Pill Chemotherapy Cabozantinib to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal …

metastasis
crizotinib
kinase inhibitor
cardiotoxic agents
cardiac disease
Cancer Care Center of O'Fallon
 (41.9 away) Contact site
  • 25 views
  • 15 Sep, 2021
  • +461 other locations
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of …

maintenance therapy
renal function
ct scan
metastasis
prophylactic cranial irradiation
Cancer Care Center of O'Fallon
 (41.9 away) Contact site
  • 0 views
  • 15 Sep, 2021
  • +148 other locations
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)

This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by …

transurethral resection
chemotherapy regimen
metastasis
mitomycin
absolute neutrophil count
Cancer Care Center of O'Fallon
 (41.9 away) Contact site
  • 0 views
  • 16 Sep, 2021
  • +157 other locations
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling …

Centralia Oncology Clinic
 (0.4 away) Contact site
  • 0 views
  • 15 Sep, 2021
  • +382 other locations
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations …

Centralia Oncology Clinic
 (0.4 away) Contact site
  • 0 views
  • 08 Sep, 2021
  • +311 other locations
Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms the EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy …

cancer
anemia
TP53
monoclonal protein
venetoclax
Centralia Oncology Clinic
 (0.4 away) Contact site
  • 0 views
  • 16 Sep, 2021
  • +384 other locations